Associated Papers
Pirtobrutinib targets BTK C481S in ibrutinib-resistant CLL but second-site BTK mutations lead to resistance.
Naeem A et al.
Blood Advances, 2023
36287227 (PubMed )
Supplement: BLOODA_ADV-2022-008447-mmc1.xlsx › Table_S3
Molecular characterization of lung squamous cell carcinoma tumors reveals therapeutically relevant alterations.
Joshi A et al.
Oncotarget, 2021
33796225 (PubMed )
Supplement: oncotarget-12-578-s005.xlsx › Variants
Select a paper to view details